DriveForShow
Posted - 6 days ago
$NEO This stock is pure agony.
Kat_Harington
Posted - 1 week ago
$NEO y’all got Kleenex hands
carminefox
Posted - 1 week ago
$NEO, this was super cheap 2 months ago and is still super cheap today. Management has been cutting useless jobs for over a year (i know someone who works there). The company is definitely heading in the right direction.
Rumor is buyout (which will be big) Or continued growth.
DriveForShow
Posted - 1 week ago
$NEO Nice to see a close above $16…It’s been a while. Let’s keep this trend going.
Stocksrunner
Posted - 2 weeks ago
$NEO This biotech stock crossed above its 200-day moving average of $14.86 and reached a high of $15.08, now trading near its new resistance at $14.95. Supported by a robust Q3 performance, the above-average volume of 1.53M suggests a possible trend shift. https://stocksrunner.com/symbol/NEO
swingingtech
Posted - 2 weeks ago
$NEO
https://wallstreetwaves.com/neo-surges-as-it-crosses-above-key-moving-average-indicator/
LetsWinSD
Posted - 2 weeks ago
$NEO how is this red on a good earnings? 🤷
LetsWinSD
Posted - 2 weeks ago
$NEO as expected. Earnings beat 🙌
DonCorleone77
Posted - 2 weeks ago
$NEO NeoGenomics sees FY24 revenue $655M-$667M, consensus $661.68M Sees FY24 adjusted EBITDA $37M- $40M.
DonCorleone77
Posted - 2 weeks ago
$NEO NeoGenomics reports Q3 EPS (14c), consensus 1c Reports Q3 revenue $168M, consensus $167.01M. Adjusted EBITDA improves 305%; ; Increasing FY Guidance to $37-$40M..."We delivered a strong third quarter, again growing revenue by double digits and increasing adjusted EBITDA by over 300%, all while serving a record number of patients," said Chris Smith, Chief Executive Officer of NeoGenomics. "Our results demonstrate our teammates' commitment to executing on our strategic priorities. This disciplined approach has enabled us to increase our adjusted EBITDA expectations for the year while continuing to position the Company for long term, sustainable growth."
Thestocktraderhubzee
Posted - 2 weeks ago
$NEO NeoGenomics Q3 2024 Adj. EPS $0.05 Beats $0.01 Estimate, Sales $167.824M Beat $167.010M Estimate
ChessGM
Posted - 2 weeks ago
$NEO Heads up alert! Only two days until Upcoming Earnings on Tuesday, 11/5/2024 Bullish (8.3) In recent developments, NeoGenomics has made significant strides in expanding its product offerings and gaining critical regulatory approvals, particularly in New York. The conditional approval for its Neo Comprehensive™ Solid Tumor assay and NeoTYPE DNA & RNA Lung test gives the company immediate access to a substantial market, which is expected to enhance its revenue streams. The financial metrics indicate a compelling outlook; the company has a P/E ratio of approximately 25, which is in line with the industry average. Analysts project an EPS growth rate of around 15% for the upcoming fiscal year, driven by increased demand for diagnostic testing and innovative solutions like the newly launched AML Express for acute myeloid leukemia. Moreover, revenue forecasts suggest a potential increase to $400 million in 2025, buoyed by recent product launches and approvals that position NeoGenomics favorably against peers in the biotechnology sector. As for upcoming earnings reports, NeoGenomics is set to announce its third-quarter 2024 financial results on November 5, 2024. Analysts anticipate a revenue of $95 million for this quarter, which would represent a year-over-year growth of approximately 12%. The consensus estimate for EPS is around $0.18, reflecting an optimistic outlook based on the company's recent performance and strategic initiatives. Historical performance shows that NeoGenomics has consistently beaten quarterly estimates, which adds to the positive sentiment surrounding the stock. Given the anticipated growth in revenue and earnings, coupled with the recent product approvals and technological advancements, the company's stock could see significant upward momentum post-earnings, solidifying its position in the market. - Funds were net buyers of $NEO during the previous reporting quarter. - Top 3 funds with large holdings in $NEO: * First Light Asset Management LLC $52MM. CGMRank: 60% * D. E. Shaw & Co $2MM. CGMRank: 85% * Balyasny Asset Management LLC $2MM. New position. CGMRank: 68% - Last 10 days performance: 3% - Last 30 days performance: -5% - Last 90 days performance: -21% Follow ChessGM! Make your move and get timely earnings alerts from ChessGM. Not a financial advice.
ZenInvestorZR
Posted - 2 weeks ago
$NEO Looks like it is loading .
LetsWinSD
Posted - 10/30/24
$NEO
LetsWinSD
Posted - 10/30/24
$NEO earnings coming Nov 5TH!
Estimize
Posted - 10/28/24
Wall St is expecting 167.01 revenue for $NEO Q3 [Reporting 11/05 BMO]
http://www.estimize.com/intro/neo?chart=historical&metric_name=revenu
LetsWinSD
Posted - 10/24/24
$NEO
LetsWinSD
Posted - 1 month ago
$Drug come over to $NEO. Earnings will be on Nov 5th. They will beat Earnings. They have consistently since new Ceo.
LetsWinSD
Posted - 1 month ago
$NEO thanks for the cheap shares. Earnings is on Nov 5th. 🚀 Will fly from there.
LetsWinSD
Posted - 1 month ago
$NEO earning coming soon. They have consecutively beat.
SM095
Posted - 1 month ago
China squeezes potential. $CPHI, $DTSS, $NEO
SideStepper
Posted - 1 month ago
$NEO
carminefox
Posted - 1 month ago
$NEO when this beats earnings again, and I mean again! This will be right back at 16. Watch and wait. And 16 will be on the low end!
Auburn66
Posted - 1 month ago
$NEO
LetsWinSD
Posted - 1 month ago
$NEO The consensus EPS estimate for the current year has increased 2.3% over the last 30 days. This means that the Wall Street analysts covering NEO are majorly in agreement about the company's potential to report better earnings than what they predicted earlier. If this is not enough, you should note that NEO currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the market. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> https://finance.yahoo.com/news/neogenomics-neo-could-support-soon-135504142.html
Kat_Harington
Posted - 1 month ago
$NEO could find a cure for cancer and still be down 2% a day
MorkKnows
Posted - 1 month ago
Another great day coming for $MARA as $BTC.X sets up a push back above $63k
$MSTR $NEO $SMCI
carminefox
Posted - 1 month ago
$NEO almost at the 52 week low. Keep beating earnings that's all we need. Plus has to climb until the big buy out from a bigger player cough cough (quest)